|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.2900 - 0.2975|
|52 Week Range||0.1800 - 0.8200|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2020 - Aug 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted a press release from its U.S. joint venture, ReGenTree LLC, on its website pursuant to the completed data analysis of its Phase 3 clinical trial (ARISE-3) with RGN-259 for the treatment of dry eye syndrome, as well as the results of pooling patient data from all three Phase 3 dry eye trials (ARISE-1, ARISE-2 and ARISE-3 comprising approximately 1,500 patients. The press release can be accessed by clicking on the following link: http://www.regenerx.com/image/ReGenTree_PR+%28MAY2021%29+FIN.pdf or navigating to RegeneRx's home page at www.RegeneRx.com.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the estimated timing of the statistical and regulatory plan for its phase 3 dry eye clinical trial (ARISE-3). This summary was provided to RegeneRx by GtreeBNT, the operating entity of its U.S. joint venture, ReGenTree LLC and sponsor of the ARISE-3 trial, which was generated at GtreeBNT's shareholder meeting on Friday March 19, 2021: http://www.regenerx.com/March-22-2021-Update-on-ARISE-3-Statistical-and-Regulatory-Plan or navigate to RegeneRx's home page at http://www.regenerx.com.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome did not meet its primary outcome measures. However, efficacy was seen in the improvement of ocular grittiness, one of the pre-specified secondary symptom endpoints in the trial. The statistically significant improvement was seen at one and two weeks after treatment, and post-exposure in a controlled adverse environment after two weeks of treatment with RGN-259 compared to placebo (p=0.0104, 0.0307, and 0.0046, respectively).